D-Pharm Phase 2 Pancreatitis

D-Pharm Ltd (TASE:DPRM) has started a Phase 2 clinical trial of DP-b99 in patients with acute high-risk inflammation of the pancreas (pancreatitis). DP-b99 is a cell protective drug that addresses multiple mechanisms damaging to insulted cells. This double-blind, placebo-controlled, multicenter study is examining for the first time DP-b99’s efficacy in patients with acute pancreatitis. The study is enrolling thirty patients to be treated, twice daily for 2 days, with either DP-b99 or placebo. The follow-up involves clinical assessment scales, monitoring of inflammatory biomarkers and abdominal imaging. In the US acute pancreatitis has an incidence of approximately 40 cases per year per 100,000 adults. Approximately 20% of patients with acute pancreatitis develop severe acute pancreatitis. DP-b99 interferes with several fundamental pathological processes, relevant for a wide range of conditions, via modulation of a range of metal dependent enzymes involved in the cell death cascade and inflammation. Results from studies in in vitro and in vivo models of pancreatitis suggest that DP-b99 can suppress some severe detrimental processes associated with the disease.

Written by

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam libero diam, elementum eget porttitor at, tincidunt at nulla.